Atai Life Sciences N.V. (ATAI)
| Previous Close | 2.0100 |
| Open | 2.0000 |
| Bid | 1.9900 x 100 |
| Ask | 2.1200 x 100 |
| Day's Range | 1.9750 - 2.0600 |
| 52 Week Range | 1.0250 - 2.8500 |
| Volume | |
| Avg. Volume | 1,610,829 |
| Market Cap | 344.05M |
| Beta (5Y Monthly) | 0.92 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2500 |
| Earnings Date | Aug 06, 2024 - Aug 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.68 |
GlobeNewswireatai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
The BPL-003 Phase 2a trial is an open-label study investigating BPL-003 as both monotherapy and adjunctive to SSRIs in patients with Treatment Resistant Depression.Initial results from the recently completed monotherapy Part 1 of the study were shared in March 2024, and showed that a single dose of BPL-003 was safe and well-tolerated, with a rapid and durable antidepressant effect lasting up to 12-weeks post-dose. Part 2 of the study will investigate a single dose of BPL-003 in patients who are
- GlobeNewswire
atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
BPL-003 is Beckley Psytech’s novel patent-protected benzoate salt formulation of 5-MeO-DMT that is administered intranasally.BPL-003 was shown to be safe and well-tolerated with a predictable pharmacokinetic profile and a reliable induction of subjective psychedelic effects with single doses of up to 12 mg in healthy participants.Subjective psychedelic effects correlated with 5-MeO-DMT exposure and had a rapid onset and short duration, with acute effects resolving in less than two hours. NEW YOR
Simply Wall St.Atai Life Sciences Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
Atai Life Sciences ( NASDAQ:ATAI ) Full Year 2023 Results Key Financial Results Net loss: US$40.2m (loss narrowed by...
